Inclusion completed

Cancer type Title Country
Breast cancer A phase Ib/II, multicenter, open-label study to evaluate the efficacy of AUY922 in combination with trastuzumab in patients with locally advanced or metasatatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-con SE
Breast cancer A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination with Anastrozole, Compared to An-astrozole alone, in Post menopausal Women With Hormone Receptor positive, Endocrine T FI
Breast cancer A prospective phase II study to evaluate alternations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression efter initial exposure to trastuzumab-taxane based treatment SE
Breast cancer Randomized phase II study of afatinib alone or in combination with vinorelbine versus investigator’s choice of treatment in patients with HER2-positive breast cancer with pro-gressive brain metastases after trastuzumab or lapatinib based therapy FI
Colorectal cancer Assessmant of safety and immunogenicity of intradermal electroporation of tetwtCEA DNA in patients with colorectal cancer SE
Colorectal cancer Randomized Double blind Placebo Controlled Gross-over Phase II study on the effects of Lactobacillus Rhamnosus GC supplementation in patients on 1st Line Chemotherapy treatment for Metastatic Coloretctal Cancer- the "lactAXE"- trial FI
Glioblastoma BIBF1120 in patient with glioblastoma and progression after standard therapy /temozolomide and radiotherapy (group 1) or after bevacizumab based secondline therapy (group 2) DK
Glioblastoma DC-CAST-GBM NO
Glioblastoma Phase I dose escalation of anti-PlGF combined with bevacizumab 10 mg/kg every 2 weeks in recurrent GBM DK
Head and Neck cancer Boron neutron capture therapy (BNCT) for the treatment of inoperable head and neck cancer FI
Lung cancer CAUY922A2206 NSCLC NO
Lymphoma A Two Stage Phase Ib Study to Investigate the Pharmocokinetics and Tolerability of Rituximab Subcutaneous Formulation in Pats With Follicular Lymphoma as Part of Maintenance Treatement FI
Lymphoma Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine,vindesine, temozolomi-de and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomi FI
Melanoma A randomised Phase II study of MK-3475 versus Chemotherapy in Pateients with Advanced Melanoma NO
Melanoma CA184025 Malign melanoma (inop. III and IV) NO
Melanoma CLGX818X2101 Locally advanced or mestastatic BRAF mutant melanoma NO
Melanoma DC-004 Unresectable metastases (Stage III or IV M1a-c-Malign melanoma) NO
Multiple diagnosis C08-315-01 Transdermally accessible tumour NO
Multiple diagnosis MOC31-PE Advanced mamma, lung, colorectal or prostate carcinoma NO
Multiple diagnosis Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MKMK)in Patients with Advanced Cancer NO
Myeloma A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma DK
Pancreatic cancer Bay86-9766 And Gemcitabine in PAncreatic Cancer (BAGPAC) NO
Pancreatic cancer Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer SE
Prostate cancer A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer FI
Prostate cancer Open, single-arm, multicenter, phase II trial investigating the safety of biweekly cabazi-taxel in metastatic castration resistant prostate cancer patients previously treated with docetaxel-containing regimen FI
Prostate cancer Safety and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer: open, non-randomised, uncontrolled, multicentre, multiple dose escalation study with randomised phase II expansion component FI
Solide tumores A phase 1, open label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function SE
Solide tumores CMEK162X2102 All solid tumors with BRAF or RAF mutation NO
Solide tumores First study of intravenous catumaxumab (Removab) in patients with EpCam expressing epithelial solid tumors DK
Solide tumores Second generation Braf inhibitor (after lead compound vemurafenib) in Braf mutated solid tumors, and extension phase in melanomas and colorectal cancer DK
Solide tumores TWEAK-antibody in patients with Fn14 expressing solid tumors, first in humans study DK